KHK dsRNA Compositions for Targeted Fructose Metabolism Reduction
Solution Overview
Problem
The unregulated metabolism of fructose by ketohexokinase (KHK) leads to various health issues such as fatty liver, dyslipidemia, insulin resistance, and metabolic syndrome, among others, due to its role in fructose phosphorylation and subsequent activation of lipogenesis.
Innovation Solution
Inhibition of KHK expression using double-stranded ribonucleic acid (dsRNA) agents that target specific RNA transcripts, including modified nucleotides and phosphorothioate linkages, to form a double-stranded region with the KHK mRNA, thereby reducing its expression.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Use of energy by moving object
If fructose metabolism is enhanced through KHK activity, then energy production increases, but harmful metabolic byproducts accumulate causing liver disease and dyslipidemia
Solution Approach 1:
The patent extracts and removes the harmful KHK enzyme function from the metabolic system using dsRNA-mediated gene silencing. By targeting KHK mRNA with complementary antisense sequences, the invention selectively eliminates the enzyme responsible for fructose phosphorylation, thereby removing the source of harmful metabolic byproducts while avoiding interference with other metabolic pathways.
Solution Approach 2:
The patent converts the harmful effect of unregulated fructose metabolism into a beneficial therapeutic outcome. By using the body's own RNA interference mechanisms to suppress KHK expression, the invention transforms the metabolic dysfunction that causes disease into a controlled therapeutic intervention that reduces liver fat accumulation and improves metabolic health.
2Productivity
If KHK expression is inhibited using dsRNA agents, then fructose metabolism is reduced, but delivery and stability of the dsRNA agent becomes challenging
Solution Approach 1:
The patent introduces chemical modifications to the dsRNA agent structure as intermediary elements that mediate between the therapeutic goal and delivery challenges. Specific modifications at terminal regions and incorporation of chemically stabilized nucleotides serve as intermediaries that protect the dsRNA from degradation while maintaining its ability to bind target mRNA, thus solving both efficacy and delivery issues.
Solution Approach 2:
The patent applies parameter changes by modifying the chemical structure of the dsRNA agent. By altering sugar pucker, base composition, and terminal modifications, the invention changes the physical and chemical parameters of the therapeutic agent to improve stability, reduce immunogenicity, and enhance cellular uptake while maintaining target specificity.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Effectively inhibits KHK activity, leading to decreased fructose metabolism and alleviation of associated health conditions like fatty liver, dyslipidemia, and insulin resistance.
Implementation Method 1
iRNA compositions which effect the RNA-induced silencing complex (RISC)-mediated cleavage of RNA transcripts of a gene encoding ketohexokinase (KHK)
Data Source
AI summary
The present invention relates to RNAi agents, e.g., dsRNA agents, targeting the ketohexokinase (KHK) gene. The invention also relates to methods of using such RNAi agents to inhibit expression of a KHK gene and to methods of treating or preventing a KHK-associated disorder in a subject.